LIVIVO - Search results -

Search results

Result 1 - 10 of total 48

Search options

Article ; Online: Underwater Wireless Sensor Networks

Elma Zanaj / Ennio Gambi / Blerina Zanaj / Deivis Disha / Nels Kola

Applied Sciences, Vol 10, Iss 6393, p

Estimation of Acoustic Channel in Shallow Water

2020 Volume 6393

Abstract: Underwater sensor networks (UWSN) include a large number of devices and sensors which are positioned in a specific area to carry out monitoring in cooperation with each other as well as data collection. In this paper it has been studied and simulated the ...

Abstract	Underwater sensor networks (UWSN) include a large number of devices and sensors which are positioned in a specific area to carry out monitoring in cooperation with each other as well as data collection. In this paper it has been studied and simulated the performance of an extremely important parameter for communication in UWSN such as the acoustic channel capacity as function of water temperature and salinity arise. The performance’s knowledge on acoustic channel may be improved with a deep study of its dependence by season, weather conditions or environmental parameters variation. If an accurate estimation of the acoustic communication capacity utilization for a given area is required, we must consider also the bottom materials of this area. The simulation results presented in this study through an improved algorithm, will help to understand better the underwater acoustic channel performance as a function of all these factors. This is of particular importance for acoustic modems designing, in order to implement suitable functionalities able to adapt the data transmission capacity of the acoustic link to the structure of the oceanic bottom and its component material.
Keywords	shallow ; bottom material ; capacity ; lifetime ; propagation ; acoustic channels ; Technology ; T ; Engineering (General). Civil engineering (General) ; TA1-2040 ; Biology (General) ; QH301-705.5 ; Physics ; QC1-999 ; Chemistry ; QD1-999
Subject code	003
Language	English
Publishing date	2020-09-01T00:00:00Z
Publisher	MDPI AG
Document type	Article ; Online
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article: Corrigendum to "Asymptomatic presentation of a congenital malformation of the portal vein with portosystemic shunt" [Radiol Case Rep 15 (2020) 2009-2014].

Musa, Juna / Madani, Kulsum / Saliaj, Kristi / Cai, Jason / Guy, Ali / Saraci, Blerina / Kola, Erisa / Hyseni, Fjolla / Saadi, Samer / Ceka, Elton

Radiology case reports

2020 Volume 15, Issue 12, Page(s) 2718

Abstract: This corrects the article DOI: 10.1016/j.radcr.2020.07.076.]. ...

Abstract	[This corrects the article DOI: 10.1016/j.radcr.2020.07.076.].
Language	English
Publishing date	2020-10-03
Publishing country	Netherlands
Document type	Published Erratum
ZDB-ID	2406300-9
ISSN	1930-0433
ISSN	1930-0433
DOI	10.1016/j.radcr.2020.09.042
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Article: Asymptomatic presentation of a congenital malformation of the portal vein with portosystemic shunt.

Musa, Juna / Madani, Kulsum / Saliaj, Kristi / Cai, Jason / Guy, Ali / Saraci, Blerina / Kola, Erisa / Ceka, Elton

Radiology case reports

2020 Volume 15, Issue 10, Page(s) 2009–2014

Abstract: Malformations of the portal venous system consist of congenital and acquired anomalies. Congenital portosystemic shunts represent rare vascular developmental anomalies that allow partial or complete diversion of blood flow from the portal venous system ... ...

Abstract	Malformations of the portal venous system consist of congenital and acquired anomalies. Congenital portosystemic shunts represent rare vascular developmental anomalies that allow partial or complete diversion of blood flow from the portal venous system to the systemic venous system, bypassing the liver. Congenital portosystemic shunts may be associated with malformations or congenital absence of the portal vein, and it was first described by John Abernethy in 1793. Most cases are diagnosed in early childhood, but some congenital shunts may remain asymptomatic and are encountered incidentally because of the widespread use of computed tomography and magnetic resonance imaging. In this report, we discuss the case of a 40-year-old female who presented to the Emergency Department with right upper quadrant pain, nausea, and vomiting. Clinical presentation and abdominal computed tomography angiography were consistent with the diagnosis of calculous cholecystitis and congenital absence of portal vein with intrahepatic portosystemic shunts. We discuss the importance of radiology in diagnosing such incidental malformations, coupled with a review of the current literature on this topic.
Language	English
Publishing date	2020-08-24
Publishing country	Netherlands
Document type	Case Reports
ZDB-ID	2406300-9
ISSN	1930-0433
ISSN	1930-0433
DOI	10.1016/j.radcr.2020.07.076
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Corrigendum to “Asymptomatic presentation of a congenital malformation of the portal vein with portosystemic shunt” [Radiol Case Rep 15 (2020) 2009-2014]

Juna Musa, MD / Kulsum Madani, MD / Kristi Saliaj, MD / Jason Cai, MD / Ali Guy, MD / Blerina Saraci, MD / Erisa Kola, MD / Fjolla Hyseni, MD / Samer Saadi, MD / Elton Ceka, MD

Radiology Case Reports, Vol 15, Iss 12, Pp 2718- (2020)

2020

Keywords	Medical physics. Medical radiology. Nuclear medicine ; R895-920
Language	English
Publishing date	2020-12-01T00:00:00Z
Publisher	Elsevier
Document type	Article ; Online
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: The Impact of Biologics and Tofacitinib on Cardiovascular Risk Factors and Outcomes in Patients with Rheumatic Disease: A Systematic Literature Review.

Nurmohamed, Michael / Choy, Ernest / Lula, Sadiq / Kola, Blerina / DeMasi, Ryan / Accossato, Paola

Drug safety

2017 Volume 41, Issue 5, Page(s) 473–488

Abstract: Introduction: Rheumatic diseases are autoimmune, inflammatory diseases often associated with cardiovascular (CV) disease, a major cause of mortality in these patients. In recent years, treatment with biologic and targeted synthetic disease-modifying ... ...

Abstract	Introduction: Rheumatic diseases are autoimmune, inflammatory diseases often associated with cardiovascular (CV) disease, a major cause of mortality in these patients. In recent years, treatment with biologic and targeted synthetic disease-modifying anti-rheumatic drugs (DMARDs), either as monotherapy or in combination with other drugs, have become the standard of treatment. In this systematic literature review, we evaluated the effect of treatment with biologic or tofacitinib on the CV risk and outcomes in these patients. Methods: A systematic search was performed in MEDLINE, Embase, the Cochrane Central Register of Controlled Trials, and Cochrane Database of Systematic Reviews for articles reporting on CV risk and events in patients with rheumatic disease treated with a biologic agent or tofacitinib. Articles identified were subjected to two levels of screening. Articles that passed the first level based on title and abstract were assessed on full-text evaluation. The quality of randomized clinical trials was assessed by Jadad scoring system and the quality of the other studies and abstracts was assessed using the Downs and Black instrument. The data extracted included study design, baseline patient characteristics, and measurements of CV risk and events. Results: Of the 5722 articles identified in the initial search, screening yielded 105 unique publications from 90 unique studies (33 clinical trials, 39 prospective cohort studies, and an additional 18 retrospective studies) that reported CV risk outcomes. A risk of bias analysis for each type of report indicated that they were of good or excellent quality. Importantly, despite some limitations in data reported, there were no indications of significant increase in adverse CV events or risk in response to treatment with the agents evaluated. Conclusions: Treatment with biologic or tofacitinib appears to be well-tolerated with respect to CV outcomes in these patients.
MeSH term(s)	Animals ; Antirheumatic Agents/adverse effects ; Antirheumatic Agents/therapeutic use ; Biological Products/adverse effects ; Biological Products/therapeutic use ; Cardiovascular Diseases/chemically induced ; Clinical Trials as Topic ; Humans ; Piperidines/adverse effects ; Piperidines/therapeutic use ; Prospective Studies ; Pyrimidines/adverse effects ; Pyrimidines/therapeutic use ; Pyrroles/adverse effects ; Pyrroles/therapeutic use ; Retrospective Studies ; Rheumatic Diseases/drug therapy ; Risk Factors
Chemical Substances	Antirheumatic Agents ; Biological Products ; Piperidines ; Pyrimidines ; Pyrroles ; tofacitinib (87LA6FU830)
Language	English
Publishing date	2017-11-28
Publishing country	New Zealand
Document type	Journal Article ; Research Support, Non-U.S. Gov't ; Review ; Systematic Review
ZDB-ID	1018059-x
ISSN	1179-1942 ; 0114-5916
ISSN (online)	1179-1942
ISSN	0114-5916
DOI	10.1007/s40264-017-0628-9
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 2127: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Efficacy of Monotherapy with Biologics and JAK Inhibitors for the Treatment of Rheumatoid Arthritis: A Systematic Review.

Emery, Paul / Pope, Janet E / Kruger, Klaus / Lippe, Ralph / DeMasi, Ryan / Lula, Sadiq / Kola, Blerina

Advances in therapy

2018 Volume 35, Issue 10, Page(s) 1535–1563

Abstract: Despite recommendations suggesting that biological and targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) should be used in combination with methotrexate in the treatment of rheumatoid arthritis (RA), up to one-third of patients with ... ...

Abstract	Despite recommendations suggesting that biological and targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) should be used in combination with methotrexate in the treatment of rheumatoid arthritis (RA), up to one-third of patients with RA are treated with monotherapy. The objective of the systematic literature review reported here was to evaluate the clinical evidence regarding the efficacy of b/tsDMARDs as monotherapy in the treatment of RA. MEDLINE Funding: Pfizer.Plain Language Summary: Plain language summary available on the journal website.
MeSH term(s)	Antirheumatic Agents/pharmacology ; Arthritis, Rheumatoid/drug therapy ; Arthritis, Rheumatoid/immunology ; Biological Products/pharmacology ; Humans ; Janus Kinase Inhibitors/pharmacology ; Medication Therapy Management ; Molecular Targeted Therapy/methods ; Treatment Outcome
Chemical Substances	Antirheumatic Agents ; Biological Products ; Janus Kinase Inhibitors
Language	English
Publishing date	2018-08-20
Publishing country	United States
Document type	Journal Article ; Research Support, Non-U.S. Gov't ; Systematic Review
ZDB-ID	632651-1
ISSN	1865-8652 ; 0741-238X
ISSN (online)	1865-8652
ISSN	0741-238X
DOI	10.1007/s12325-018-0757-2
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 2101: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Shedding light on the intricate puzzle of ghrelin's effects on appetite regulation.

Kola, Blerina / Korbonits, Márta

The Journal of endocrinology

2009 Volume 202, Issue 2, Page(s) 191–198

Abstract: Ghrelin, a hormone primarily produced by the stomach, has a wide range of metabolic and non-metabolic effects. It also stimulates food intake through activation of various hypothalamic and brain stem neurons. A series of recent studies have explored the ... ...

Abstract	Ghrelin, a hormone primarily produced by the stomach, has a wide range of metabolic and non-metabolic effects. It also stimulates food intake through activation of various hypothalamic and brain stem neurons. A series of recent studies have explored the intracellular mechanisms of the appetite-inducing effect of ghrelin in the hypothalamus, shedding light on the intricate mechanisms of appetite regulation. AMP-activated protein kinase (AMPK) is a key metabolic enzyme involved in appetite regulation. Calmodulin kinase kinase 2 (CaMKK2) has been identified as an upstream kinase of AMPK and a key mediator in the effect of ghrelin on AMPK activity. The fatty acid pathway, hypothalamic mitochondrial respiration, and uncoupling protein 2 have been outlined as downstream targets of AMPK and mediators of ghrelin's appetite stimulating effect. This short overview summarises the present data in this field.
MeSH term(s)	Animals ; Appetite Regulation/physiology ; Calcium-Calmodulin-Dependent Protein Kinase Kinase/metabolism ; Cannabinoids/metabolism ; Cannabinoids/pharmacology ; Drug Interactions ; Fatty Acids/metabolism ; Ghrelin/metabolism ; Ghrelin/physiology ; Humans ; Ion Channels/metabolism ; Mitochondrial Proteins/metabolism ; Uncoupling Protein 2
Chemical Substances	Cannabinoids ; Fatty Acids ; Ghrelin ; Ion Channels ; Mitochondrial Proteins ; UCP2 protein, human ; Ucp2 protein, mouse ; Uncoupling Protein 2 ; Calcium-Calmodulin-Dependent Protein Kinase Kinase (EC 2.7.11.17) ; Camkk2 protein, mouse (EC 2.7.11.17)
Language	English
Publishing date	2009-08
Publishing country	England
Document type	Journal Article ; Research Support, Non-U.S. Gov't ; Review
ZDB-ID	3028-4
ISSN	1479-6805 ; 0022-0795
ISSN (online)	1479-6805
ISSN	0022-0795
DOI	10.1677/JOE-09-0056
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Uh III Zs.133: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Asymptomatic presentation of a congenital malformation of the portal vein with portosystemic shunt

Juna Musa, MD / Kulsum Madani, MD / Kristi Saliaj, MD / Jason Cai, MD / Ali Guy, MD / Blerina Saraci, MD / Erisa Kola, MD / Elton Ceka, MD

Radiology Case Reports, Vol 15, Iss 10, Pp 2009-

2020 Volume 2014

Abstract: ABSTRACT: Malformations of the portal venous system consist of congenital and acquired anomalies. Congenital portosystemic shunts represent rare vascular developmental anomalies that allow partial or complete diversion of blood flow from the portal ... ...

Abstract	ABSTRACT: Malformations of the portal venous system consist of congenital and acquired anomalies. Congenital portosystemic shunts represent rare vascular developmental anomalies that allow partial or complete diversion of blood flow from the portal venous system to the systemic venous system, bypassing the liver. Congenital portosystemic shunts may be associated with malformations or congenital absence of the portal vein, and it was first described by John Abernethy in 1793. Most cases are diagnosed in early childhood, but some congenital shunts may remain asymptomatic and are encountered incidentally because of the widespread use of computed tomography and magnetic resonance imaging. In this report, we discuss the case of a 40-year-old female who presented to the Emergency Department with right upper quadrant pain, nausea, and vomiting. Clinical presentation and abdominal computed tomography angiography were consistent with the diagnosis of calculous cholecystitis and congenital absence of portal vein with intrahepatic portosystemic shunts. We discuss the importance of radiology in diagnosing such incidental malformations, coupled with a review of the current literature on this topic.
Keywords	Case report ; Congenital Anomalous Portal Vein ; Portosystemic Shunt ; Medical physics. Medical radiology. Nuclear medicine ; R895-920
Subject code	610
Language	English
Publishing date	2020-10-01T00:00:00Z
Publisher	Elsevier
Document type	Article ; Online
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Metformin to reduce metabolic complications and inflammation in patients on systemic glucocorticoid therapy: a randomised, double-blind, placebo-controlled, proof-of-concept, phase 2 trial.

Pernicova, Ida / Kelly, Stephen / Ajodha, Sharon / Sahdev, Anju / Bestwick, Jonathan P / Gabrovska, Plamena / Akanle, Olufunso / Ajjan, Ramzi / Kola, Blerina / Stadler, Marietta / Fraser, William / Christ-Crain, Mirjam / Grossman, Ashley B / Pitzalis, Costantino / Korbonits, Márta

The lancet. Diabetes & endocrinology

2020 Volume 8, Issue 4, Page(s) 278–291

Abstract: Background: An urgent need to reduce the metabolic side-effects of glucocorticoid overexposure has been recognised, as glucocorticoid excess can lead to Cushing's syndrome, which is associated with high morbidity. We aimed to evaluate the potential of ... ...

Abstract	Background: An urgent need to reduce the metabolic side-effects of glucocorticoid overexposure has been recognised, as glucocorticoid excess can lead to Cushing's syndrome, which is associated with high morbidity. We aimed to evaluate the potential of metformin to reverse such effects while sparing the anti-inflammatory benefits of glucocorticoids. Methods: We did a randomised, double-blind, placebo-controlled, proof-of-concept, phase 2 trial involving four hospitals in the UK. Patients without diabetes were eligible if they were between the ages of 18 and 75 years with an inflammatory disease treated with continuous prednisolone (≥20 mg/day for ≥4 weeks and remaining on ≥10 mg/day for the subsequent 12 weeks, or its cumulative dose-equivalent). Eligible patients were randomly allocated (1:1) to either the metformin or placebo groups, using a computer-generated randomisation table stratified according to age and BMI. Metformin and placebo were administered orally for 12 weeks in escalating doses: 850 mg/day for the first 5 days, 850 mg twice a day for the next 5 days, and 850 mg three times a day subsequently. The primary outcome was the between-group difference in visceral-to-subcutaneous fat area ratio over 12 weeks, assessed by CT. Secondary outcomes included changes in metabolic, bone, cardiovascular, and inflammatory parameters over 12 weeks. Our analysis followed a modified intention-to-treat principle for the primary outcome. This study is registered with ClinicalTrials.gov, NCT01319994. Findings: Between July 17, 2012, and Jan 14, 2014, 849 patients were assessed for study eligibility, of which 53 were randomly assigned to receive either metformin (n=26) or placebo (n=27) for 12 weeks. 19 patients in the metformin group and 21 in the placebo group were eligible for the primary outcome analysis. Both groups received an equivalent cumulative dose of glucocorticoids (1860 mg prednisolone-equivalent [IQR 1060-2810] in the metformin group vs 1770 mg [1020-2356] in the placebo group); p=0·76). No change in the visceral-to-subcutaneous fat area ratio between the treatment groups was observed (0·11, 95% CI -0·02 to 0·24; p=0·09), but patients in the metformin group lost truncal subcutaneous fat compared with the placebo group (-3835 mm Interpretation: No significant changes in the visceral-to-subcutaneous fat area ratio between the treatment groups were observed; however, metformin administration did improve some of the metabolic profile and clinical outcomes for glucocorticoid-treated patients with inflammatory disease, which warrants further investigation. Funding: Barts Charity and Merck Serono.
MeSH term(s)	Adult ; Aged ; Autoimmune Diseases/drug therapy ; Autoimmune Diseases/immunology ; Autoimmune Diseases/physiopathology ; Double-Blind Method ; Female ; Glucocorticoids/adverse effects ; Glucocorticoids/therapeutic use ; Humans ; Hypoglycemic Agents/therapeutic use ; Inflammation/drug therapy ; Inflammation/prevention & control ; Male ; Metabolic Diseases/drug therapy ; Metabolic Diseases/prevention & control ; Metformin/therapeutic use ; Middle Aged ; Proof of Concept Study ; Treatment Outcome ; Young Adult
Chemical Substances	Glucocorticoids ; Hypoglycemic Agents ; Metformin (9100L32L2N)
Language	English
Publishing date	2020-02-25
Publishing country	England
Document type	Clinical Trial, Phase II ; Journal Article ; Multicenter Study ; Randomized Controlled Trial ; Research Support, Non-U.S. Gov't
ISSN	2213-8595
ISSN (online)	2213-8595
DOI	10.1016/S2213-8587(20)30021-8
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article: Dynamic testing in Cushing's syndrome.

Kola, Blerina / Grossman, Ashley B

Pituitary

2007 Volume 11, Issue 2, Page(s) 155–162

Abstract: Endogenous Cushing's syndrome (CS) results from chronic exposure to excess glucocorticoids. CS can be ACTH-dependent, caused by ACTH-secreting pituitary or ectopic tumours, or ACTH-independent, caused by cortisol-secreting adrenal tumours. CS can be an ... ...

Abstract	Endogenous Cushing's syndrome (CS) results from chronic exposure to excess glucocorticoids. CS can be ACTH-dependent, caused by ACTH-secreting pituitary or ectopic tumours, or ACTH-independent, caused by cortisol-secreting adrenal tumours. CS can be an extremely difficult diagnosis to make, and assessment will include clinical, biochemical and radiological evaluation. Several screening tests are used for the confirmation of hyper-cortisolaemia and its differentiation from other, more frequent, clinical abnormalities, such as simple obesity, hypertension, depression etc. Other dynamic tests are useful for establishing the aetiology. We have reviewed the current literature on the diagnosis of CS, and based on these data and our own experience, suggest the most useful tests and diagnostic criteria to be used. We conclude that even though laboratory testing is a fundamental part of the investigation of patients with CS, the interpretation of the tests should always be performed with extreme care, as none of the tests has proven fully capable of distinguishing all cases of CS. The biochemical results should be interpreted jointly with the clinical aspects and the radiology findings in a probabilistic matrix, and not as part of a uniform algorithm.
MeSH term(s)	Adrenocorticotropic Hormone/physiology ; Circadian Rhythm/physiology ; Cushing Syndrome/classification ; Cushing Syndrome/diagnosis ; Cushing Syndrome/etiology ; Dexamethasone ; Diagnosis, Differential ; Humans ; Hydrocortisone/blood ; Hydrocortisone/urine ; Pituitary Function Tests ; Saliva/chemistry
Chemical Substances	Dexamethasone (7S5I7G3JQL) ; Adrenocorticotropic Hormone (9002-60-2) ; Hydrocortisone (WI4X0X7BPJ)
Language	English
Publishing date	2007-11-22
Publishing country	United States
Document type	Journal Article ; Review
ZDB-ID	1385151-2
ISSN	1573-7403 ; 1386-341X
ISSN (online)	1573-7403
ISSN	1386-341X
DOI	10.1007/s11102-007-0079-x
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 6139: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

To top

Full text online

More links

Kategorien

Inter-library loan at ZB MED

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

Inter-library loan at ZB MED

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

Inter-library loan at ZB MED

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito